Dr. John Leonard on Top Lymphoma Studies at the 2015 ASH Annual Meeting

December 6, 2015
John Leonard, MD

Leonard says some of the more interesting studies to crop up in the field of Hodgkin's lymphoma include ones that utilize checkpoint inhibitors, as well as one of the first combination immunotherapies to be used in the disease

John Leonard, MD, medical oncologist, Weill Cornell Medicine and NewYorkPresbyterian Hospital , discusses the top lymphoma studies to be presented at the 57th American Society of Hematology (ASH) Annual Meeting. Leonard says some of the more interesting studies to crop up in the field of Hodgkin's lymphoma include ones that utilize checkpoint inhibitors, as well as one of the first combination immunotherapies to be used in the disease — a duet of brentuximab vedotin and ipilimumab.

Leonard goes on to say there is more data that involves brentuximab alongside chemotherapy in elderly patients, which would be in place of ABVD chemotherapy. ABVD chemotherapy is a standard of care for older patients with Hodgkin's lymphoma, though the treatment has proven less effective and more toxic to patients over time.